* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Host and pathogen - Buffalo Ontology Site
Innate immune system wikipedia , lookup
Cancer immunotherapy wikipedia , lookup
Psychoneuroimmunology wikipedia , lookup
Immunosuppressive drug wikipedia , lookup
Hygiene hypothesis wikipedia , lookup
African trypanosomiasis wikipedia , lookup
Schistosoma mansoni wikipedia , lookup
Hepatitis B wikipedia , lookup
Multiple sclerosis research wikipedia , lookup
Polyclonal B cell response wikipedia , lookup
Transmission (medicine) wikipedia , lookup
“Asiyah” Yu Lin, Zuoshuang Xiang, Yongqun “Olive” He University of Michigan Medical School Ann Arbor, MI 48109, USA 1 Classification of Brucella Bacteria, Proteobacteria, a-Proteobacteria, Rhizobiales, Brucellaceae Brucella listed as CDC and NIH priority category B pathogen Species Host B. abortus cattle, human B. canis dogs, foxes, coyotes, human B. melitensis sheep, goats, human B. neotomae desert wood rats B. ovis rams B. suis pigs, human Gram negative, cocco-bacillus; facultative intracellular bacterium 2 Symptoms of Brucellosis Animals: • Chronic infection leading to abortion and infertility • Clinical signs & symptoms vary with species - metritis, spondylitis, lameness, paralysis - testicular swelling, lympadenitis, splenitis Humans: • Clinical signs & symptoms: fever (Undulant Fever) anorexia, back pain, fatigue, malaise, myalgia, sweats, weight loss. • Mortality rate is low; abortions NOT common • Clinical manifestations - a lot, including reactive arthritis (a type of spondylitis) 3 Brucellosis Ontology (BO) An extension of IDO-core Uniqueness of BO: The first zoonosis disease ontology to be developed. The first Gram-negative bacteria to be carefully modeled under the scope of IDO. The first “select agent” to be modeled. Goal: data integration and text mining 4 Statistics of BO BO Classes in total : 452 Clinical Entities IDO (full) OGMS SYMP FLU TRANS VO Biological Entities GO PRO CHEBI NCBI taxonomy Investigational Entities OBI IAO 5 Developing methodology Top-down & Bottom-up (scenarios) Design patterns Host-pathogen transmission Brucella virulence factors (pathogenesis) Intentional release and epidemiology Diagnosis and treatment Protective antigen 6 Host-pathogen interaction/transmission Entry Infects phagocytic cells Abortion Dead fetus, placentas & secretions Regional Lymph Nodes Infection Systemic Spread Liver, spleen, other lymph nodes; uterus in ungulates Unpasteurized milk, Cheese or dairy products Transmission to other vertebrates = Zoonosis 7 Host-pathogen & transmission modeling human brucellosis human brucellosis pathogen role is_realized_by bearer_of B.abortus bearer_of cattle brucellosis pathogen role human brucellosis disease course cattle brucellosis disease course has_function Brucella-infected is_realized_by Brucella-contaminated milk producing function cow brucellosis patient role bearer_of brucellosis patient Brucella-contaminated milk drinking process is_realized_ by drinking function human is_a is_a cattle brucellosis brucellosis is_a bearer_of Brucella-contaminated milk producing process is_a disposition has_specified_ output Brucella-contaminated is_specified milk _ input_of is_a Brucelloa host role bearer_of abortion process is_realized_by is_realized_by is_a unpasteurized milk inheres_in has_part is_realized_by bearer_of cow Scenario: A brucellosis patient got infected by drinking the unpasteurized Brucellacontaminated milk, which was produced by a Brucella-infected cow. is_realized_by B. abortus infectious course is_a brucella infectious course 8 Brucella Virulence factors Brucella virulence factors are aerobic facultative intracellular pathogen; and it is unusual in: It doesn’t have classical virulence factors. It maintain an intracellular existence within its host cells, such as macrophages, dendritic cells, placental trophoblasts, epithelial cells The interactions with those host cells dictate the outcomes of infection. Candidate GO terms: intracellular viral protein transport (GO:0019060 biological process) establishment of localization in cell (GO:0051649 biological process) entry into host cell (GO:0030260 biological process) Other terms: cellular host? … 9 Brucella virulence factor modeling Senario: Brucella invading into macrophages, the Brucella virb1 is the virulence factor participant_in participant_in Brucella Process of Brucella’s replication in macrophages Process of Brucella’s survival in macrophages has_part establishment of Brucella intracellular infection Brucella entry into macrophages Entry into host cell (GO:0030260) is_realized_by Brucella virb1 bearer_of is_a Brucella protein bearer_of Brucella virulence factor disposition virulence factor bearer_of is_a is_a has_part Brucella protein virulence factor is_a is_a Brucella virulence factor After reasoning, ‘Brucella virb1’ is_a Brucella protein virulence factor Statistics: >200 Brucella virulence factors, collected by He Lab, stored in BO already. 10 Epidemiology and Intentional release Brucella can be intentionally released for bioterrorism Scenario: Brucella organisms could be released in aerosol form, by accidental spills of culture suspensions or live vaccines, or in liquids such as dairy products or water. Brucellosis has fairly low fatality rate, but could be used as an incapacitating agent, as the disease tends to be chronic, requiring prolonged treatment 11 Brucella intentional release modeling bioterrorism agent role bearer_of Brucella is_a is_specified_input_of aerosolized Brucella Brucella intentional release is_specified_output_of is_specified_input_of Brucella aerosolization disinfectant role bearer_of bleach (a disinfectant) has_part is_a is_specified_input_of is_a planned process is_a bleach disinfection of aerosolized Brucella is_a Brucella containment 12 Diagnosis of brucellosis Brucellosis infects many species, especially cattle, sheep, goats, pigs. Different Brucella types infect different species preferentially. Brucellosis presents typically as abortion in cattle. Diagnosis can only be confirmed by laboratory tests, such as PCR ! 13 PCR diagnosis based on Brucella OMP-2 Detection OMP-2 forward primer has_specified_input PCR test has_specified_output PCR product of PCR has_specified_input for OMP-2reverse primer detection test for detection of of Brucella OMP-2 is_specified_input_of Brucella Is_specified_output_of Brucellacontaminated OMP-2 body fluids amplifies amplifies part_of 169bp’s region located in B. abortus OMP-2 gene part_of is_ denoted _by is_denoted_by part_of B. abortus genome part_of B. abortus genome sequence data OMP-2 reverse primer sequence data OMP-2 forward primer sequence data part_of OMP-2 gene is_denoted_by B. melitensis genome codes_for OMP-2 protein hasSize:169 is_denoted _by data item B. meltitensis genome sequence data is_a letter string Is_subset_of (transitive property) end_with start_with Is_subset_of (transitive property) is_a PCR product sequence data is_a sequence data * sequence data OBI_0000973 14 Continue with PCR diagnosis… is_a diagnosis is_about Brucellosis diagnosis clinical manifestation of brucellosis is_a inheres_in data item ??? brucellosis patient is_a has_role laboratory finding of OMP2-detection has_specified_output laboratory test is_a brucellosis patient role PCR test for detection of brucella OMP-2 is_realized_by brucellosis disease course is_realized_by Brucellosis pathogen role specimen bearer_of is_a contains Brucella-contaminated is_a Brucella body fluids brucellosis patient derived specimen is_a pathogen part_of has_part fever process patient is_a brucellosis patient is_a Homo sapiens is_a infected host is_a host infected with Brucella 15 Protective antigen Protective antigens are those antigens that are specifically targeted by the acquired immune response of the host, and when introduced into the host body, are able to stimulate the production of antibodies and/or cell-mediated immunity against certain pathogens or the causes of other diseases. 16 Protective antigen modeling immune response (GO_0006955) is_a adaptive immune response is_a Brucella protective antigen stimulated acquired immune response is_a Brucella-specific protective T cell mediated immune response is_realized_by antigen role (OBI_1110034) is_a Brucella protective antigen role bearer_of MaterialEntity(OBI) antigen is_a (OBI_1110034) is_a Brucella protective antigen 17 Treatment A scenario from WHO recommend treatment is as following : Treatment of uncomplicated cases in adults and children eight years of age and older: doxycycline 100 mg twice a day for six weeks + streptomycin 1 g daily for two to three weeks. 18 Treatment Modeling brucellosis treatment objective is_a objective specification has_part Is_concritization_of (WHO standard treatment specification for human brucellosis) realizes Doxycycline specification in WHO standard treatment for human brucellosis WHO standard doxycycline treatment for human brucellosis patient role is_a age is_specified_input_of has_role inheres_in brucellosis patient 100 mg twice a day for six weeks is_concretized_as is_realized_by quality plan specification part_of WHO standard treatment for human brucellosis >=8 is_a doxycycline is_a human * Green box shows the difficulties 19 A proposal modeling for age Specifically, adults and children eight years of age and older 8 year has_quality specified quality is_a age inheres_in brucellosis patient eight years of age and older has_function viable function * Black and blue arrows differ two kinds of modeling is_realized_by living process has_temporal_region connected temporal region of living till now start_with starting temporal boundary is_a is_a the 8th year temporal boundary end_with ending temporal boundary is_a 20 Open for discussion Interactions between upper and lower ontologies When upper ontology changes… Downstream ontologies should provide new terms to upper ontologies The granularity for modeling For example, shall we model the molecular level of virulence factor? Symptoms and signs: The established vocabulary is not sufficient, neither OGMS nor Symptom Ontology How to model: (IAO’s scope) 100 mg twice a day for six weeks 21 Acknowledgments OBI and IDO developers Funding: NIH-NIAID R01AI081062 22